Atossa is developing afimoxifene gel for atypical ductal hyperplasia (ADH), a condition affecting about 100,000 new US patients each year, and which leads to breast cancer within five years in 5-11% of cases (Coopey et al. 2011). A Phase II trial for intraductal fulvestrant should also start by YE15.
